Antithrombotic endothelial graft
The clinical adoption of tissue-engineered vascular conduits (TEVCs) developed earlier by seeding autologous bone marrow cells onto biodegradable polymeric scaffolds has been hindered by a high incidence of graft stenosis in prior TEVC clinical trials.
The researchers developed new type of TEVCs by coating luminal surfaces of decellularized human umbilical arteries with iPSC-derived endothelial cells (ECs) under shear stress.
TEVCs provided immediate antithrombotic function and promoted the replacement with host EC and vascular smooth muscle cell after implantation into a rat model.
https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(24)00406-5
https://sciencemission.com/Fully-biologic-endothelialized-tissue-engineered-vascular-conduits
